1181-P: Effect and Feasibility of High Dose Eplerenone in Type 2 Diabetes: A Mirad Substudy

1181-P: Effect and Feasibility of High Dose Eplerenone in Type 2 Diabetes: A Mirad Substudy

The use of mineralocorticoid receptor antagonists (MRA) as anti-hypertensive therapy has been limited due to concern of potential hyperkalemia among patients with T2D. The aim of this study was to investigate the effect on blood pressure (BP) and feasibility of use of selective MRA eplerenone in T2D...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2019-06, Vol.68 (Supplement_1)
Hauptverfasser: BRANDT-JACOBS, NIELS HØEG, RASMUSSEN, JON BJARKE, JOHANSEN, MARIE-LOUISE, ROSSIGNOL, PATRICK, FABER, JENS, SCHOU, MORTEN, KISTORP, CAROLINE MICHAELA
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title Diabetes (New York, N.Y.)
container_volume 68
creator BRANDT-JACOBS, NIELS HØEG
RASMUSSEN, JON BJARKE
JOHANSEN, MARIE-LOUISE
ROSSIGNOL, PATRICK
FABER, JENS
SCHOU, MORTEN
KISTORP, CAROLINE MICHAELA
description The use of mineralocorticoid receptor antagonists (MRA) as anti-hypertensive therapy has been limited due to concern of potential hyperkalemia among patients with T2D. The aim of this study was to investigate the effect on blood pressure (BP) and feasibility of use of selective MRA eplerenone in T2D. We randomized 140 patients with T2D and established or high risk of cardiovascular disease to either eplerenone or placebo for 26 weeks. Target study medication dose was 200 mg/day or 100mg/day for patients with an eGFR >60 or 40-60 ml/min/1,73m2, respectively. Outcomes of this substudy was change in 24h-ABPM, office-BP from baseline and incident hyperkalemia (s-K ≥ 5.5 mmol/L). A decrease was found in office systolic BP, in the eplerenone group as compared with placebo (-6 mmHg, [-11; -1], P=0.03). Mean 24h-systolic- (SBP) and diastolic BP (DBP) decreased significantly with eplerenone (SBP: -5 mmHg [-8; -2], P
doi_str_mv 10.2337/db19-1181-P
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_2337_db19_1181_P</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2337_db19_1181_P</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_2337_db19_1181_P3</originalsourceid><addsrcrecordid>eNqVzrFqwzAUhWFREqjbdOoL3L2o0bUgjr2FxiFLwJAMhQxCjq8aFcc2uvbgt29N-wLhDGf5h0-IV1TvsdbJsioxlYhrlMWDiDDVqdRx8jkTkVIYS0zS5FE8MX8rpVa_i8T5r84gd44uPdimgh1Z9qWvfT9C62Dvv66wbZkg72oK1LQNgW_gNHYEMWy9LaknzmADBx9sBceh5H6oxoWYO1szvfz_s3jb5aePvbyEljmQM13wNxtGg8pMfjP5zSQyhb6v_gEw90pz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1181-P: Effect and Feasibility of High Dose Eplerenone in Type 2 Diabetes: A Mirad Substudy</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>BRANDT-JACOBS, NIELS HØEG ; RASMUSSEN, JON BJARKE ; JOHANSEN, MARIE-LOUISE ; ROSSIGNOL, PATRICK ; FABER, JENS ; SCHOU, MORTEN ; KISTORP, CAROLINE MICHAELA</creator><creatorcontrib>BRANDT-JACOBS, NIELS HØEG ; RASMUSSEN, JON BJARKE ; JOHANSEN, MARIE-LOUISE ; ROSSIGNOL, PATRICK ; FABER, JENS ; SCHOU, MORTEN ; KISTORP, CAROLINE MICHAELA</creatorcontrib><description>The use of mineralocorticoid receptor antagonists (MRA) as anti-hypertensive therapy has been limited due to concern of potential hyperkalemia among patients with T2D. The aim of this study was to investigate the effect on blood pressure (BP) and feasibility of use of selective MRA eplerenone in T2D. We randomized 140 patients with T2D and established or high risk of cardiovascular disease to either eplerenone or placebo for 26 weeks. Target study medication dose was 200 mg/day or 100mg/day for patients with an eGFR &gt;60 or 40-60 ml/min/1,73m2, respectively. Outcomes of this substudy was change in 24h-ABPM, office-BP from baseline and incident hyperkalemia (s-K ≥ 5.5 mmol/L). A decrease was found in office systolic BP, in the eplerenone group as compared with placebo (-6 mmHg, [-11; -1], P=0.03). Mean 24h-systolic- (SBP) and diastolic BP (DBP) decreased significantly with eplerenone (SBP: -5 mmHg [-8; -2], P &lt;0.001; DBP: -3 mmHg [-4; -1] P &lt;0.001). The difference in 24h ABPM-change between groups at end-of-study being borderline significant (-3 mmHg [-7; 1], P=0.1). Number of patients with incident hyperkalemia did not differ (eplerenone vs. placebo 6 vs. 2, P = 0.27); with no incidences of severe hyperkaliemia (s-K ≥6.0 mmol/L). We conclude eplerenone to be a feasible option in the treatment of T2D patients with hypertension and normal mean eGFR. Figure: 24-h ABPM change; comparison of baseline and end-of-study.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db19-1181-P</identifier><language>eng</language><ispartof>Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>BRANDT-JACOBS, NIELS HØEG</creatorcontrib><creatorcontrib>RASMUSSEN, JON BJARKE</creatorcontrib><creatorcontrib>JOHANSEN, MARIE-LOUISE</creatorcontrib><creatorcontrib>ROSSIGNOL, PATRICK</creatorcontrib><creatorcontrib>FABER, JENS</creatorcontrib><creatorcontrib>SCHOU, MORTEN</creatorcontrib><creatorcontrib>KISTORP, CAROLINE MICHAELA</creatorcontrib><title>1181-P: Effect and Feasibility of High Dose Eplerenone in Type 2 Diabetes: A Mirad Substudy</title><title>Diabetes (New York, N.Y.)</title><description>The use of mineralocorticoid receptor antagonists (MRA) as anti-hypertensive therapy has been limited due to concern of potential hyperkalemia among patients with T2D. The aim of this study was to investigate the effect on blood pressure (BP) and feasibility of use of selective MRA eplerenone in T2D. We randomized 140 patients with T2D and established or high risk of cardiovascular disease to either eplerenone or placebo for 26 weeks. Target study medication dose was 200 mg/day or 100mg/day for patients with an eGFR &gt;60 or 40-60 ml/min/1,73m2, respectively. Outcomes of this substudy was change in 24h-ABPM, office-BP from baseline and incident hyperkalemia (s-K ≥ 5.5 mmol/L). A decrease was found in office systolic BP, in the eplerenone group as compared with placebo (-6 mmHg, [-11; -1], P=0.03). Mean 24h-systolic- (SBP) and diastolic BP (DBP) decreased significantly with eplerenone (SBP: -5 mmHg [-8; -2], P &lt;0.001; DBP: -3 mmHg [-4; -1] P &lt;0.001). The difference in 24h ABPM-change between groups at end-of-study being borderline significant (-3 mmHg [-7; 1], P=0.1). Number of patients with incident hyperkalemia did not differ (eplerenone vs. placebo 6 vs. 2, P = 0.27); with no incidences of severe hyperkaliemia (s-K ≥6.0 mmol/L). We conclude eplerenone to be a feasible option in the treatment of T2D patients with hypertension and normal mean eGFR. Figure: 24-h ABPM change; comparison of baseline and end-of-study.</description><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqVzrFqwzAUhWFREqjbdOoL3L2o0bUgjr2FxiFLwJAMhQxCjq8aFcc2uvbgt29N-wLhDGf5h0-IV1TvsdbJsioxlYhrlMWDiDDVqdRx8jkTkVIYS0zS5FE8MX8rpVa_i8T5r84gd44uPdimgh1Z9qWvfT9C62Dvv66wbZkg72oK1LQNgW_gNHYEMWy9LaknzmADBx9sBceh5H6oxoWYO1szvfz_s3jb5aePvbyEljmQM13wNxtGg8pMfjP5zSQyhb6v_gEw90pz</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>BRANDT-JACOBS, NIELS HØEG</creator><creator>RASMUSSEN, JON BJARKE</creator><creator>JOHANSEN, MARIE-LOUISE</creator><creator>ROSSIGNOL, PATRICK</creator><creator>FABER, JENS</creator><creator>SCHOU, MORTEN</creator><creator>KISTORP, CAROLINE MICHAELA</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20190601</creationdate><title>1181-P: Effect and Feasibility of High Dose Eplerenone in Type 2 Diabetes: A Mirad Substudy</title><author>BRANDT-JACOBS, NIELS HØEG ; RASMUSSEN, JON BJARKE ; JOHANSEN, MARIE-LOUISE ; ROSSIGNOL, PATRICK ; FABER, JENS ; SCHOU, MORTEN ; KISTORP, CAROLINE MICHAELA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_2337_db19_1181_P3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BRANDT-JACOBS, NIELS HØEG</creatorcontrib><creatorcontrib>RASMUSSEN, JON BJARKE</creatorcontrib><creatorcontrib>JOHANSEN, MARIE-LOUISE</creatorcontrib><creatorcontrib>ROSSIGNOL, PATRICK</creatorcontrib><creatorcontrib>FABER, JENS</creatorcontrib><creatorcontrib>SCHOU, MORTEN</creatorcontrib><creatorcontrib>KISTORP, CAROLINE MICHAELA</creatorcontrib><collection>CrossRef</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BRANDT-JACOBS, NIELS HØEG</au><au>RASMUSSEN, JON BJARKE</au><au>JOHANSEN, MARIE-LOUISE</au><au>ROSSIGNOL, PATRICK</au><au>FABER, JENS</au><au>SCHOU, MORTEN</au><au>KISTORP, CAROLINE MICHAELA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1181-P: Effect and Feasibility of High Dose Eplerenone in Type 2 Diabetes: A Mirad Substudy</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2019-06-01</date><risdate>2019</risdate><volume>68</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>The use of mineralocorticoid receptor antagonists (MRA) as anti-hypertensive therapy has been limited due to concern of potential hyperkalemia among patients with T2D. The aim of this study was to investigate the effect on blood pressure (BP) and feasibility of use of selective MRA eplerenone in T2D. We randomized 140 patients with T2D and established or high risk of cardiovascular disease to either eplerenone or placebo for 26 weeks. Target study medication dose was 200 mg/day or 100mg/day for patients with an eGFR &gt;60 or 40-60 ml/min/1,73m2, respectively. Outcomes of this substudy was change in 24h-ABPM, office-BP from baseline and incident hyperkalemia (s-K ≥ 5.5 mmol/L). A decrease was found in office systolic BP, in the eplerenone group as compared with placebo (-6 mmHg, [-11; -1], P=0.03). Mean 24h-systolic- (SBP) and diastolic BP (DBP) decreased significantly with eplerenone (SBP: -5 mmHg [-8; -2], P &lt;0.001; DBP: -3 mmHg [-4; -1] P &lt;0.001). The difference in 24h ABPM-change between groups at end-of-study being borderline significant (-3 mmHg [-7; 1], P=0.1). Number of patients with incident hyperkalemia did not differ (eplerenone vs. placebo 6 vs. 2, P = 0.27); with no incidences of severe hyperkaliemia (s-K ≥6.0 mmol/L). We conclude eplerenone to be a feasible option in the treatment of T2D patients with hypertension and normal mean eGFR. Figure: 24-h ABPM change; comparison of baseline and end-of-study.</abstract><doi>10.2337/db19-1181-P</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)
issn 0012-1797
1939-327X
language eng
recordid cdi_crossref_primary_10_2337_db19_1181_P
source EZB-FREE-00999 freely available EZB journals; PubMed Central
title 1181-P: Effect and Feasibility of High Dose Eplerenone in Type 2 Diabetes: A Mirad Substudy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A53%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1181-P:%20Effect%20and%20Feasibility%20of%20High%20Dose%20Eplerenone%20in%20Type%202%20Diabetes:%20A%20Mirad%20Substudy&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=BRANDT-JACOBS,%20NIELS%20H%C3%98EG&rft.date=2019-06-01&rft.volume=68&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db19-1181-P&rft_dat=%3Ccrossref%3E10_2337_db19_1181_P%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true